In this Issue:
Adjuvant trastuzumab: 1 year the optimal
MBC survival times in routine clinical practice
3- vs 4-drug chemo regimens in node-positive BC
BRCA1 mutation does not worsen survival
Ethinylestradiol effective in pre-treated MBC
Everolimus + exemestane in visceral metastases
Pegylated liposomal doxorubicin: toxicities in elderly
Adjuvant bevacizumab in triple-negative BC
Integrating fulvestrant into treatment for MBC
Adjuvant therapy: small absolute benefits in early BC
Please login below to download this issue (PDF)